Takeda Pharmaceutical Company Limited (NYSE:TAK) Holdings Boosted by Financial Avengers Inc.

Financial Avengers Inc. boosted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 117.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,211 shares of the company’s stock after purchasing an additional 3,355 shares during the period. Financial Avengers Inc.’s holdings in Takeda Pharmaceutical were worth $88,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TAK. EverSource Wealth Advisors LLC grew its position in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares in the last quarter. BNP Paribas Financial Markets grew its position in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares in the last quarter. Smithfield Trust Co grew its position in Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Erste Asset Management GmbH purchased a new position in Takeda Pharmaceutical during the 3rd quarter worth approximately $52,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at $59,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 2.0 %

Shares of NYSE:TAK opened at $13.46 on Wednesday. The firm has a fifty day moving average of $13.88 and a two-hundred day moving average of $13.87. The firm has a market capitalization of $42.83 billion, a P/E ratio of 23.21, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.